Semaglutide is a medication that has garnered significant attention in the field of weight management. Initially approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of type 2 diabetes, it was later approved in 2021 for chronic weight management. This breakthrough drug belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists.

What is Semaglutide?

Semaglutide is a synthetic version of the human glucagon-like peptide-1 hormone. It works by mimicking an intestinal hormone that regulates appetite and food intake. By activating GLP-1 receptors in the brain, semaglutide reduces hunger and increases feelings of fullness, leading to reduced calorie intake and subsequent weight loss.

Approval and Mechanism of Action:

Semaglutide was first approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes in 2017. In June 2021, it received another FDA approval for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Semaglutide works by mimicking the GLP-1 (glucagon-like peptide-1) hormone, which plays a crucial role in regulating appetite and food intake. By activating GLP-1 receptors, semaglutide helps reduce hunger, increase feelings of fullness, and slow down gastric emptying, leading to reduced calorie intake and subsequent weight loss.

Dosage and Administration:

The dosage of semaglutide for weight loss typically starts at 0.25 mg once weekly, administered via subcutaneous injection. The dose is gradually increased over time, usually in 4-week intervals, until reaching the maintenance dose of 2.4 mg once weekly. The medication is available in a pre-filled pen device, making it convenient for patients to self-administer. As with any medication, it's crucial to follow the prescribing physician's instructions carefully for optimal results.

Research Findings: Impressive Results

The efficacy of semaglutide for weight loss was demonstrated in the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program. In the STEP 1 trial, published in 2021, participants taking semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. This significant weight loss is what has made semaglutide a game-changer in obesity treatment.

Weight Regain After Discontinuation

While semaglutide has shown impressive results in weight loss, an important consideration is what happens when patients stop taking the medication. Recent studies have shed light on this aspect:

1. Long-term Weight Regain: Earlier research indicated that abruptly stopping semaglutide often led to substantial weight regain. After 68 weeks of treatment, patients regained an average of 11.6% of their body weight by week 120. One study noted that participants regained two-thirds of their prior weight loss one year after withdrawing from semaglutide treatment.
2. Variable Outcomes: A more recent study from January 2024 presented a more nuanced picture. Among 20,274 participants:
   • 17.7% regained all or more of their lost weight
   • 56.2% maintained their weight loss or continued to lose weight
3. Tapering Strategy: Research presented at the European Congress on Obesity (ECO) 2024 suggests that gradually tapering off semaglutide, combined with lifestyle changes, may be key to preventing weight regain. Patients who tapered off the medication over 9 weeks maintained a stable body weight for the first 26 weeks after discontinuation, with an average weight loss of 1.5% at week 26.

Expert Insights

Dr. Henrik Gudbergsen, lead researcher and Chief Medical Officer at Embla, commented on the tapering approach: "The combination of support in making lifestyle changes and slow tapering seems to allow patients to avoid regaining weight after coming off semaglutide. I think that's testament to the fact that they actually have learned more about emotional eating behaviors, lifestyle, food, exercise, and so on, and not just relied on semaglutide for the weight loss. They're actually in control."

Future Considerations

While the data on tapering is promising, some health professionals have expressed concerns about potential weight regain over periods longer than 26 weeks. More long-term studies are needed to draw confident conclusions about the best strategies for maintaining weight loss after discontinuing semaglutide.

Semaglutide represents a significant advancement in weight loss treatment. However, its long-term effectiveness and the management of patients post-treatment remain active areas of research. As with any weight loss intervention, the importance of sustainable lifestyle changes cannot be overstated in achieving and maintaining a healthy weight.

‍